Zynex (NASDAQ:ZYXI) Updates FY 2024 Earnings Guidance

Zynex (NASDAQ:ZYXI) issued an update on its FY 2024 earnings guidance on Thursday morning. The company provided EPS guidance of 0.200- for the period, compared to the consensus EPS estimate of 0.200. The company issued revenue guidance of $200.0 million-, compared to the consensus revenue estimate of $200.5 million. Zynex also updated its Q4 guidance to at least $0.09 EPS.

Analysts Set New Price Targets

ZYXI has been the subject of a number of recent analyst reports. HC Wainwright raised their price objective on Zynex from $16.00 to $17.00 and gave the stock a “buy” rating in a research report on Friday. Royal Bank of Canada lowered their price target on Zynex from $12.00 to $11.00 and set an “outperform” rating for the company in a report on Tuesday, October 8th.

Zynex Stock Performance

NASDAQ:ZYXI traded up $0.53 during trading hours on Friday, hitting $9.12. 264,477 shares of the company were exchanged, compared to its average volume of 173,892. The company has a debt-to-equity ratio of 1.79, a current ratio of 4.06 and a quick ratio of 3.22. Zynex has a 52-week low of $7.04 and a 52-week high of $13.77. The stock has a market capitalization of $289.79 million, a price-to-earnings ratio of 39.65 and a beta of 0.54. The company’s 50 day moving average price is $8.01 and its 200-day moving average price is $9.18.

Zynex (NASDAQ:ZYXI) last announced its quarterly earnings data on Thursday, October 24th. The company reported $0.07 earnings per share for the quarter, beating analysts’ consensus estimates of $0.06 by $0.01. The firm had revenue of $49.97 million for the quarter, compared to analyst estimates of $50.83 million. Zynex had a net margin of 3.12% and a return on equity of 14.15%. The business’s quarterly revenue was up .1% compared to the same quarter last year. During the same period in the previous year, the company earned $0.10 earnings per share. As a group, research analysts forecast that Zynex will post 0.2 earnings per share for the current year.

Insider Activity

In related news, COO Anna Lucsok sold 8,083 shares of Zynex stock in a transaction dated Wednesday, August 7th. The stock was sold at an average price of $8.03, for a total transaction of $64,906.49. Following the completion of the sale, the chief operating officer now owns 16,980 shares of the company’s stock, valued at $136,349.40. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In other Zynex news, Director Joshua R. Disbrow acquired 7,000 shares of the business’s stock in a transaction dated Monday, July 29th. The shares were purchased at an average price of $8.32 per share, for a total transaction of $58,240.00. Following the completion of the purchase, the director now directly owns 72,000 shares of the company’s stock, valued at $599,040. The trade was a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, COO Anna Lucsok sold 8,083 shares of the business’s stock in a transaction on Wednesday, August 7th. The shares were sold at an average price of $8.03, for a total transaction of $64,906.49. Following the transaction, the chief operating officer now owns 16,980 shares of the company’s stock, valued at $136,349.40. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 52.13% of the company’s stock.

About Zynex

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.